These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11126208)

  • 41. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents.
    Maahs D; de Serna DG; Kolotkin RL; Ralston S; Sandate J; Qualls C; Schade DS
    Endocr Pract; 2006; 12(1):18-28. PubMed ID: 16524859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.
    Tagliaferri M; Scacchi M; Pincelli AI; Berselli ME; Silvestri P; Montesano A; Ortolani S; Dubini A; Cavagnini F
    Int J Obes Relat Metab Disord; 1998 Sep; 22(9):836-41. PubMed ID: 9756240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Herbal simulation of ephedrine and caffeine in treatment of obesity.
    Dulloo AG
    Int J Obes Relat Metab Disord; 2002 May; 26(5):590-2. PubMed ID: 12032740
    [No Abstract]   [Full Text] [Related]  

  • 44. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity.
    Greenway F; Herber D; Raum W; Herber D; Morales S
    Obes Res; 1999 Jul; 7(4):370-8. PubMed ID: 10440593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of hypothalamic obesity with caffeine and ephedrine.
    Greenway FL; Bray GA
    Endocr Pract; 2008 Sep; 14(6):697-703. PubMed ID: 18996788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Weight reduction effects of a black soy peptide supplement in overweight and obese subjects: double blind, randomized, controlled study.
    Kwak JH; Ahn CW; Park SH; Jung SU; Min BJ; Kim OY; Lee JH
    Food Funct; 2012 Oct; 3(10):1019-24. PubMed ID: 22739624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
    Astrup A; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Larsen TM
    Lancet; 2008 Nov; 372(9653):1906-1913. PubMed ID: 18950853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
    Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
    JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
    Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
    Mulligan K; Zackin R; Von Roenn JH; Chesney MA; Egorin MJ; Sattler FR; Benson CA; Liu T; Umbleja T; Shriver S; Auchus RJ; Schambelan M;
    J Clin Endocrinol Metab; 2007 Feb; 92(2):563-70. PubMed ID: 17090640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of caffeine and albuterol on body composition and metabolic rate.
    Liu AG; Arceneaux KP; Chu JT; Jacob G; Schreiber AL; Tipton RC; Yu Y; Johnson WD; Greenway FL; Primeaux SD
    Obesity (Silver Spring); 2015 Sep; 23(9):1830-5. PubMed ID: 26239482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
    Persky AM; Ng C; Song MH; Lancaster ME; Balderson DE; Paulik MA; Brouwer KL
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):442-8. PubMed ID: 15366324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study.
    Astrup A; Toubro S; Cannon S; Hein P; Madsen J
    Metabolism; 1991 Mar; 40(3):323-9. PubMed ID: 2000046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship of blood pressure, heart rate and behavioral mood state to norepinephrine kinetics in younger and older men following caffeine ingestion.
    Arciero PJ; Gardner AW; Benowitz NL; Poehlman ET
    Eur J Clin Nutr; 1998 Nov; 52(11):805-12. PubMed ID: 9846593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.